Research programme: liver X receptor modulators - Allergan

Drug Profile

Research programme: liver X receptor modulators - Allergan

Alternative Names: VTP 38443; VTP-4

Latest Information Update: 11 Apr 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Vitae Pharmaceuticals
  • Developer Allergan; Vitae Pharmaceuticals
  • Class Small molecules
  • Mechanism of Action Liver X receptor agonists; Liver X receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Acute coronary syndromes
  • Discontinued Alzheimer's disease; Atherosclerosis

Most Recent Events

  • 31 Mar 2015 Vitae Pharmaceuticals plans a phase I trial for VTP 38443 in acute coronary syndrome
  • 16 Dec 2014 Discontinued - Preclinical for Alzheimer's disease in USA (PO)
  • 16 Dec 2014 Discontinued - Preclinical for Atherosclerosis in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top